Relmada Phase 3 Reliance II trial for REL-1017 in MDD deemed futile at interim analysis

RELMADA THERAPEUTICS, INC.

DMC interim analysis indicates Reliance II is futile, unlikely to meet primary efficacy endpoint with statistical significance.
No new safety signals reported; DMC did not identify any safety concerns.
Relmada to evaluate next steps for REL-1017 program; continues development of REL-P11 for metabolic disease.
Cash and cash equivalents ~$54.1M as of Sep 30, 2024, providing runway.
Sergio Traversa, CEO, expressed disappointment and gratitude to participants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.